RxDoctor Payments Data

Joanne Romboli Hill

Nurse Practitioner · Londonderry, NHNPI 1609101880

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 102 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AbbVie at 59.4% of the total. Reporting peaked in 2021 at $805 and has fallen 64.5% since, to $286 in 2025. Among nurse practitioner clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,637in general payments, 2019–2025

Across 102 payments — averaging $16.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$972
  • Daiichi Sankyo Inc.$246
  • Novo Nordisk$119
  • Pfizer$116
  • Lilly USA, LLC$112
  • Biohaven Pharmaceutical Holding Company Ltd.$32
  • plus $41 from 2 others

What the payments were for

  • Food & beverage$1,637100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,637 in reported general payments places this provider in the 95th percentile of 714 nurse practitioner providers in New Hampshire.

See all nurse practitioner providers in New Hampshire

Medicare billing

Part B allowed, 2024
$53,224
Medicare patients
144
Services billed
955

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide31$53,544
MounjaroTirzepatide26$26,889
TrulicityDulaglutide24$26,308
EliquisApixaban20$11,647
JardianceEmpagliflozin12$10,874
Bupropion XlBupropion Hcl36$882
Levothyroxine Sodium74$802
Atorvastatin Calcium107$679
Omeprazole47$576
Rosuvastatin Calcium76$511
Lisinopril104$444
Pantoprazole Sodium50$428
Pravastatin Sodium17$426
Famotidine24$417
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine12$386

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$119$53,54431 claims
Lilly USA, LLCMounjaro, Trulicity$112$53,19750 claims
PfizerEliquis$116$11,64720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 714 nurse practitioner providers in New Hampshire.

Other nurse practitioner in Londonderry

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →